CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.
By Michael McCaughan
There are two things everybody knows about Medicare coverage for physician-administered cancer drugs.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Revision of the EU’s pharmaceutical legislation will include a new definition of unmet need, but getting it wrong could have unintended consequences for pricing and reimbursement.
European regulators could investigate alternative ways of offering early advice to companies in relation to the Health Technology Assessment Regulation, given that official scientific advice slots are limited, a senior figure at EUCOPE says.
CMS Administrator Oz punted on a GLP-1 question in an interview, suggesting it was because his agency will be acting soon.
For manufacturers, the model could lead to a substantial reductions in prices for high cost physician administered drugs in Medicare, Medicaid and the 340B program.
The Immunization Safety Office leveraged a “coordinated network of complementary surveillance systems” to monitor COVID-19 vaccine risks during the pandemic, but its communications faced challenges and were often intertwined with CDC efforts to promote vaccination, NASEM report finds.
Claims for the dermatological appearing on websites and social media were challenged by Dupixent marketer Sanofi. Galderma said it would comply with the National Advertising Division’s recommendations, a move that underscores the challenging times for DTC advertisers.
FDA’s former CBER director is joining industry as senior VP of molecule discovery and head, infectious disease at Eli Lilly.
